Provided by Tiger Trade Technology Pte. Ltd.

VanEck Healthcare TruSector ETF

30.48
+0.01520.05%
Post-market: 30.46-0.0195-0.06%16:10 EDT
Volume:523
Turnover:15.96K
Market Cap:609.59K
PE:- -
High:30.48
Open:30.46
Low:30.46
Close:30.46
52wk High:30.68
52wk Low:24.78
Shares:20.00K
Float Shares:20.00K
Volume Ratio:0.50
T/O Rate:2.62%
Dividend:0.09
Dividend Rate:0.28%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Merck, Amgen Share Gains Contribute to Dow's 161-Point Climb

Dow Jones
·
Aug 19

Moderna Stock Price Doubles on Melanoma Vaccine News

Dow Jones
·
Aug 19

Merck Shares Touch Record High, Last up 9.6%

THOMSON REUTERS
·
Aug 19

Shares of Moderna Rise 87%, Merck Rise 6.8% After Skin Cancer Vaccine Succeeds in Late-Stage Trial

THOMSON REUTERS
·
Aug 19

Sector Update: Healthcare

MT Newswires Live
·
Aug 19

Biotech Stocks Jump Premarket After Moderna's Melanoma Vaccine with Merck Succeeds in Large Trial

THOMSON REUTERS
·
Aug 19

The Bond Selloff is Rattling Investors, but Here's Why They Shouldn't Expect a Deeper Stock Downturn

Dow Jones
·
Aug 19

Stocks to Watch: Oracle, SK Hynix, Moderna, Unitree

Dow Jones
·
Aug 19

Moderna, Merck, La-Z-Boy, SK Hynix, and More Stocks That Explain Today's Market

Dow Jones
·
Aug 19

U.S. Stocks on the MOVE-Estee Lauder, Target, Analog Devices

Reuters
·
Aug 19

Merck, Moderna Say Potential Melanoma Therapy Shows 'Statistically Significant Improvement' in Late-Stage Trial

MT Newswires Live
·
Aug 19

Bond Yields, Persian Gulf Outlooks Cap Wall Street Pre-Bell; Asia, Europe Off

MT Newswires Live
·
Aug 19

Moderna Stock Surges 70%, Merck Rises 6%. at Last, a Successful Cancer Vaccine.

Dow Jones
·
Aug 19

Moderna and Merck Say Melanoma Skin Cancer Vaccine Meets Goals in Large Trial

Reuters
·
Aug 19

Moderna Vaccine Cuts Recurrence and Spread of High-Risk Melanoma, Raising New Treatment Hope

Reuters
·
Aug 19

Merck Shares Rise 1.9% Premarket

THOMSON REUTERS
·
Aug 19

Merck, Moderna Say Melanoma Skin Cancer Vaccine Meets Goals in Large Trial

Reuters
·
Aug 19

Merck: Safety Profiles of Intismeran and Keytruda in Trial were Consistent with Prior Reported Studies for the Combination

THOMSON REUTERS
·
Aug 19

Merck: Phase 3 Interpath-001 Trial of Intismeran Autogene Plus Keytruda Met Primary Endpoint of Recurrence Free Survival

THOMSON REUTERS
·
Aug 19

Merck: Co, Moderna Announce Positive Results from Phase 3 Interpath-001 Trial for Patients with Completely Resected Stage Iib-Iv Melanoma

THOMSON REUTERS
·
Aug 19